| Thomas G Adams Ii, PT | |
|
2717 S Arlington Rd, Akron, OH 44312-4725 | |
| (330) 245-1791 | |
| (330) 245-1793 |
| Full Name | Thomas G Adams Ii |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 26 Years |
| Location | 2717 S Arlington Rd, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144210683 | NPI | - | NPPES |
| PT08486 | Other | OH | OT PT ATC BOARD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT08486 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physical Therapy And Sportscare Centers, Inc. | 6406859453 | 3 |
News Archive
NeuroPace, Inc. today announced that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RNS® System, a novel investigational device that utilizes responsive neurostimulation to monitor and interrupt abnormal electrical activity in the brain before seizures occur. The PMA application is for an indication to treat people with medically refractory partial onset epilepsy originating from one or two locations in the brain.
The SCCA House, an 80-unit patient housing facility for cancer patients and their families and caregivers, was dedicated today during ceremonies at its South Lake Union location. The facility is the second such "home away from home" building that is operated by the Seattle Cancer Care Alliance. Rooms are scheduled to be available to SCCA patients by the end of the month.
A team of scientists at the Weizmann Institute of Science in Israel revealed that the ability to detect smells predicts recovery and long-term survival in patients who had a severe brain injury. The study, published in the journal Nature, shows that the simple "sniff test," which is inexpensive and convenient, could help doctors to diagnose and develop treatments for patients who have brain injuries and unconsciousness.
Scientists studying hatchling fish have made a new advance in studying a chemical in the brain that impacts on movement.
Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.
› Verified 2 days ago
| Provider Name | Physical Therapy And Sportscare Centers, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1114976024 PECOS PAC ID: 6406859453 Enrollment ID: O20060814000232 |
News Archive
NeuroPace, Inc. today announced that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RNS® System, a novel investigational device that utilizes responsive neurostimulation to monitor and interrupt abnormal electrical activity in the brain before seizures occur. The PMA application is for an indication to treat people with medically refractory partial onset epilepsy originating from one or two locations in the brain.
The SCCA House, an 80-unit patient housing facility for cancer patients and their families and caregivers, was dedicated today during ceremonies at its South Lake Union location. The facility is the second such "home away from home" building that is operated by the Seattle Cancer Care Alliance. Rooms are scheduled to be available to SCCA patients by the end of the month.
A team of scientists at the Weizmann Institute of Science in Israel revealed that the ability to detect smells predicts recovery and long-term survival in patients who had a severe brain injury. The study, published in the journal Nature, shows that the simple "sniff test," which is inexpensive and convenient, could help doctors to diagnose and develop treatments for patients who have brain injuries and unconsciousness.
Scientists studying hatchling fish have made a new advance in studying a chemical in the brain that impacts on movement.
Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas G Adams Ii, PT 2717 S Arlington Rd, Akron, OH 44312-4725 Ph: (330) 245-1791 | Thomas G Adams Ii, PT 2717 S Arlington Rd, Akron, OH 44312-4725 Ph: (330) 245-1791 |
News Archive
NeuroPace, Inc. today announced that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RNS® System, a novel investigational device that utilizes responsive neurostimulation to monitor and interrupt abnormal electrical activity in the brain before seizures occur. The PMA application is for an indication to treat people with medically refractory partial onset epilepsy originating from one or two locations in the brain.
The SCCA House, an 80-unit patient housing facility for cancer patients and their families and caregivers, was dedicated today during ceremonies at its South Lake Union location. The facility is the second such "home away from home" building that is operated by the Seattle Cancer Care Alliance. Rooms are scheduled to be available to SCCA patients by the end of the month.
A team of scientists at the Weizmann Institute of Science in Israel revealed that the ability to detect smells predicts recovery and long-term survival in patients who had a severe brain injury. The study, published in the journal Nature, shows that the simple "sniff test," which is inexpensive and convenient, could help doctors to diagnose and develop treatments for patients who have brain injuries and unconsciousness.
Scientists studying hatchling fish have made a new advance in studying a chemical in the brain that impacts on movement.
Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.
› Verified 2 days ago
Kathy J Peterson, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Cortney Ann Myer, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1 Perkins Sq, Akron, OH 44308 Phone: 330-543-2110 | |
Rehabilitation And Health Center Inc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1799 Akron Peninsula Rd, Suite 312, Akron, OH 44313 Phone: 330-752-7265 | |
Dr. Brenda Renee Runion, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, Akron, OH 44307 Phone: 330-344-6190 | |
Dr. Michael John Golz, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-4854 Fax: 330-375-4074 | |
Lisa Dietsche, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Michael Green, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3367 |